A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Pancreatic Cancer

In brief

Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.

Key facts

Study ID

NCT01632306

Run by

Eli Lilly and Company

People needed

13

Starts

2013-03-01

Expected to finish

2015-06-01

Last updated by the study team

2019-01-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Metastatic pancreatic cancer with metastases amenable to biopsy
• Willingness to provide tissue and blood samples for research purposes
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

You may not qualify if…

• History of islet cell, acinar cell, or cystadenocarcinomas
• Prior cytotoxic chemotherapy for metastatic disease, except prior gemcitabine or FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin)
• Radiation therapy, immunotherapy or biologic therapy <28 days prior to study entry

Where it is running

• Mayo Clinic of Jacksonville — Jacksonville, Florida, United States
• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.